The School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.
Biomaterials. 2010 Jun;31(18):4846-54. doi: 10.1016/j.biomaterials.2010.02.015. Epub 2010 Mar 25.
This study aimed to determine the optimal dosage range of NT-3 in the soluble form or loaded with chitosan carriers by using NT-3/chitosan carriers to support the survival and proliferation of neural stem cells (NSCs) and induce them to differentiate into desired phenotypes. NSCs were co-cultured with chitosan carriers loaded with different doses of NT-3. As the control, NSCs were cultured in the defined medium, into which were added different doses of NT-3 in the soluble form every day. The ELISA kit was used to study the NT-3 releasing kinetics, which showed that, in the initial co-culture stage from 1 h to 14 weeks, the chitosan carriers loaded with different doses of NT-3 released NT-3 stably and constantly. The 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was conducted to measure the cell viability, and the immunocytochemical methods were adopted to quantitatively analyze the phenotypes differentiating from the NSCs. Compared to the 100 ng NT-3 daily addition group (1400 ng over 14 days), the 25 ng, 50 ng and 200 ng NT-3 daily addition group showed dramatically shorter processes length and much lower differentiation percentage from NSCs into neurons. By contrast, the NT-3 (25 ng)-chitosan carriers group had not only higher cell viability, but also similar processes length and differentiation percentage from NSCs into neurons to the 100 ng NT-3 daily addition group. The method developed in this study significantly reduced the NT-3 amount required to support the survival, proliferation and differentiation of NSCs in vitro. Meanwhile, the chitosan carriers used here provided an ideal 3-dimensional scaffold for the adhesion, migration, proliferation and differentiation of NSC and the differentiated cells. Therefore, this method may open a new field for the large-scaled culture and amplification of NSCs in vitro to replace the lost neural cells, meanwhile lower the consumption of neurotrophic factors in the cell transplantation therapy of brain and spinal injury.
本研究旨在通过使用 NT-3/壳聚糖载体来支持神经干细胞(NSCs)的存活、增殖,并诱导其分化为所需表型,确定可溶性 NT-3 或负载壳聚糖载体的 NT-3 的最佳剂量范围。将 NSCs 与负载不同剂量 NT-3 的壳聚糖载体共同培养。作为对照,将 NSCs 培养在定义的培养基中,每天向其中加入不同剂量的可溶性 NT-3。酶联免疫吸附测定(ELISA)试剂盒用于研究 NT-3 的释放动力学,结果表明,在最初的 1 小时至 14 周的共同培养阶段,负载不同剂量 NT-3 的壳聚糖载体稳定且持续地释放 NT-3。3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)测定法用于测量细胞活力,并采用免疫细胞化学方法定量分析从 NSCs 分化而来的表型。与每天添加 100 ng NT-3(14 天共 1400 ng)的组相比,每天添加 25 ng、50 ng 和 200 ng NT-3 的组显示出明显更短的突起长度和更低的 NSCs 向神经元分化比例。相比之下,NT-3(25 ng)-壳聚糖载体组不仅具有更高的细胞活力,而且突起长度和 NSCs 向神经元分化比例与每天添加 100 ng NT-3 的组相似。本研究中开发的方法显著降低了体外支持 NSCs 存活、增殖和分化所需的 NT-3 量。同时,此处使用的壳聚糖载体为 NSC 和分化细胞的粘附、迁移、增殖和分化提供了理想的三维支架。因此,该方法可能为体外大规模培养和扩增 NSCs 以替代丢失的神经细胞开辟新领域,同时降低脑和脊髓损伤细胞移植治疗中神经营养因子的消耗。
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008-2
Sci China Life Sci. 2010-3-7
Sheng Li Xue Bao. 2007-6-25
Biochem Biophys Res Commun. 2007-6-15
Front Bioeng Biotechnol. 2023-9-12
Front Bioeng Biotechnol. 2022-6-21
Signal Transduct Target Ther. 2022-6-17
Front Bioeng Biotechnol. 2021-6-14